Foundation Medicine GmbH
- Address
- Nonnenwald 2, 82377 Penzberg, Germany
Oncology at Foundation Medicine GmbH
Clinical research at this testing site focuses on neoplasms, with studies centered on advanced cancers and the search for better treatment options. The work is aimed at evaluating new therapies and comparing them with current standard approaches to improve disease control.
- Metastatic castration-resistant prostate cancer is being studied to assess whether a new treatment approach can better delay disease progression.
- Advanced breast cancer research is exploring treatment strategies for hormone-receptor-positive, HER2-negative disease with specific genetic features.
These trials reflect a strong focus on cancer treatment effectiveness, especially for patients with limited options after standard therapies.
Cancer Treatment Research
The site in Penzberg, Germany, is also involved in clinical studies designed to refine how targeted and combination treatments are used in difficult-to-treat cancers. The goal is to determine whether newer combinations can improve response rates and slow progression more effectively than comparator regimens.
- Research in prostate cancer is testing whether a targeted therapy combination can improve radiographic progression-free survival.
- Studies in breast cancer are assessing whether a combination approach can increase the objective response rate in advanced disease.
Overall, the research program is concentrated in oncology, with emphasis on improving outcomes for patients with advanced solid tumors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1F. Hoffmann-La Roche AG2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Foundation Medicine GmbH
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss | F. Hoffmann-La Roche AG | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inavolisib | 2 | Unknown | 2026-04-07 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.